Jiangsu

Quiénes somos

  • 5 de abril de 2022
    Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer
  • enero 1, 1970
    Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM